United States health regulators have authorised a second antiviral pill against COVID-19, providing another easy-to-use medication to battle the rising tide of Omicron infections.
The US Food and Drug Administration authorised Merck’s molnupiravir on Thursday. The approval comes a day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.
Merck’s drug was shown to reduce hospitalisations and deaths by about 30 percent in a clinical trial of high-risk individuals early in the course of the illness. The FDA authorised the oral drug for the treatment of mild-to-moderate COVID-19 in adults who are at risk for severe disease, and for whom alternative coronavirus treatments are not accessible or clinically appropriate.
Molnupiravir’s ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects
The Pfizer pill works differently and does not carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing than Merck’s, reducing hospitalisation and death by nearly 90 percent among high-risk patients.
Both the Merck and Pfizer pills could, however, be promising tools for those who are sick with COVID-19, especially in the face of the fast-spreading Omicron variant, which is now dominant in the US and beyond.
“As new variants of the virus continue to emerge, it is crucial to expand the country’s arsenal of COVID-19 therapies using emergency use authorisation,” said Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research.
Antiviral pills, including Merck’s, are expected to be effective against Omicron because they do not target the spike protein where most of the variant’s worrisome mutations reside.
To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”
Dr Nick Kartsonis, Merck’s senior vice president of clinical research, said the company’s scientists are still studying the drug and they hope to eventually get it approved for use in children.
The restrictions on molnupiravir were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.
Source: Reuters
In other news – Asante Spends Time With Her Grandmother – VIDEO
Nothing is cuter than the bond and love between children and their grandmothers.
It is every parent’s dream that their children meet their parents before they pass away, and Murdah Bongz is blessed that this moment is now taking place. Learn more
